Zobrazeno 1 - 10
of 275
pro vyhledávání: '"D. Jaubert"'
Publikováno v:
Kidney International. 99:1247-1248
Autor:
N. Resseguier, Mickaël Bobot, Thomas Robert, D. Jaubert, Noémie Jourde-Chiche, A. Duval, G. Lano, Stanislas Bataille, D. Bouchouareb, Philippe Brunet
Publikováno v:
Nephrologie & Therapeutique
Introduction Les patients hemodialyses chroniques (HD) constituent une population a haut risque de COVID-19 severe, et ne peuvent rester confines. La prevalence de l’immunisation contre le SARS-CoV-2 parmi les patients HD et les soignants, apres la
Autor:
Amandine Gouverneur, Juliette Coutureau, Jérémy Jové, Magali Rouyer, Angela Grelaud, Sophie Duc, Stéphane Gérard, Denis Smith, Alain Ravaud, Cécile Droz, Marie-Agnès Bernard, Régis Lassalle, Annie Forrier-Réglat, Pernelle Noize, D. Smith, N. Tubiana-Mathieu, P. Michel, R. Guimbaud, Y. Becouarn, F. Viret, D. Larregain-Fournier, Y. Botreau, P. Texereau, D. Auby, L. Gautier-Felizot, I. Loury-Larivière, E. Brudieux, L. Cany, C. Lecaille, D. Jaubert, P. Guichard, O. Bernard, L. Vives, N. Taoubi, M. Martinez, F. Burki, I. Roque, F. Thouveny, M.H. Gaspard
Publikováno v:
Clinical Colorectal Cancer
Clinical Colorectal Cancer, Elsevier, 2019, 18 (1), pp.e150-e162. ⟨10.1016/j.clcc.2018.11.005⟩
Clinical Colorectal Cancer, Elsevier, 2019, 18 (1), pp.e150-e162. ⟨10.1016/j.clcc.2018.11.005⟩
International audience; BACKGROUND: Metastatic colorectal cancer (mCRC) is increasingly treated using targeted therapies. Their real-life evaluation is insufficient, especially in elderly and frail patients. The aim was to describe use, safety, and e
Autor:
Xavier Pivot, Gilles Romieu, Marc Debled, Jean-Yves Pierga, Pierre Kerbrat, Thomas Bachelot, Alain Lortholary, Marc Espié, Pierre Fumoleau, Daniel Serin, Jean-Philippe Jacquin, Christelle Jouannaud, Maria Rios, Sophie Abadie-Lacourtoisie, Laurence Venat-Bouvet, Laurent Cany, Stéphanie Catala, David Khayat, Laetitia Gambotti, Iris Pauporté, Celine Faure-Mercier, Sophie Paget-Bailly, Julie Henriques, Jean Marie Grouin, C Piprot, L Cals, L Chaigneau, F Demarchi, T N'Guyen, U Stein, C Villanueva, JL Bréau, AK Chouahnia, P Saintigny, F Boué, P deSaint-Hilaire, I Guimont, N Grossat, B Valenza, E Lévy, J Médioni, C Delbaldo, J Grenier, D Pouessel, S Lavau-Denès, C Falandry, C Fournel-Fédérico, G Freyer, S Tartas, V Trillet-Lenoir, F Bons, G Auclerc, S Chièze, N Raban, C Tournigand, S Trager-Maury, G Bousquet, C Cuvier, S Giacchetti, A Hocini, C LeMaignan, JL Misset, D Avenin, C Beerblock, J Gligorov, P Rivera, H Roché, P Bougnoux, N Hajjaji, O Capitain, R Delva, P Maillart, P Soulié, H Bonnefoi, M Durand, N Madranges, L Mauriac, P Chollet, AF Dillies, X Durando, JP Ferrière, C Mouret-Reynier, JM Nabholtz, I Van Praagh, P Cottu, V Diéras, A Durieux, M Galotte, V Girre, S Henry, I Iurisci, M Jouve, V Laurence, L Mignot, S Piperno-Neumann, P Tresca, B Coudert, E Ferrant, F Mayer, AC Vanneuville, J Bonneterre, V Servent, L Vanlemmens, P Vennin, JP Guastalla, P Biron, L Dupuy-Brousseau, L Lancry, I Ray-Coquard, P Rebattu, O Trédan, JM Extra, F Rousseau, C Tarpin, M Fabbro, E Luporsi, L Uwer, B Weber, D Berton-Rigaud, E Bourbouloux, M Campone, JM Ferrero, P Follana, R Largillier, V Mari, B Costa, H Curé, JC Eymard, N Jovenin, D Lebrun, J Meunier, G Yazbek, D Gedoin, B Laguerre, C Lefeuvre, E Vauléon, A Chevrier, C Guillemet, M Leheurteur, O Rigal, I Tennevet, C Veyret, E Brain, M Guiterrez, F Mefti-Lacheraf, T Petit, F Dalenc, L Gladieff, F André, S Delaloge, J Domont, J Ezenfis, M Spielmann, P Guillet, V Boulanger, J Provençal, L Stefani, C Alliot, D Ré, C Bellaiche-Miccio, G Boutan-Laroze, R Vanica, P Dion, G Sadki-Benaoudia, A Marti, AL Villing, B Slama, JL Dutel, S Nguyen, R Saad, O Arsène, Z Merad-Boudia, H Orfeuvre, J Egreteau, MJ Goudier, R Lamy, B Leduc, C Sarda, B Salles, C Agostini, I Cauvin, A Dufresne, M Mangold, S Lebouvier-Sadot, B Audhuy, JC Barats, S Cluet-Dennetière, D Zylberait, G Netter, L Gautier-Felizot, I Cojean-Zelek, A Plantade, S Vignot, E Guardiola, P Marti, I deHartingh, R Diab, A Dietmann, S Ruck, C Portois, S Oddou-Lagranière, F Campos-Gazeau, A Bourcier, F Priou, JF Geay, D Mayeur, P Gabez, R ElAmarti, M Combe, P Raichon-Patru, P Amsalhem, J Dauba, D Paraiso, F Guinet, B Duvert, M Litor, F Kara-Slimane, A Bichoffe, N Denizon, P Soyer, F Morvan, S Van-Hulst, L Vincent, C Alleaume, P Ibanez-Martin, A Youssef, Z Tadrist, E Carola, C Pourny, JF Toccanier, N Al-Aukla, K Mahour-Bacha, J Salvat, P Nouyrigat, S Clippe, MC Gouttebel, L Vedrine, G Clavreul, O Collard, D Mille, Y Goubely, R Hervé, S Kirscher, F Plat, V Delecroix, V Ligeza-Poisson, D Coeffic, D Fric, C Garnier, C Leyronnas, T Kreitman, E Teissier, P Martin, S Rohart deCordoue, C ElKouri, JF Ramée, C Laporte, O Bernard, T Altwegg, A Darut-Jouve, JP Dujols, F Darloy, C Giraud, V Pottier-Kyndt, N Achour, S Drony, M Moriceau, C Sarrazin, JC Legueul, J Mandet, D Besson, AC Hardy-Bessard, J Cretin, P Houyau, E Achille, D Genêt, H Thévenot, A Moran-Ribon, JM Pavlovitch, P Ardisson, I Moullet, B Couderc, V Fichet, F Burki, A Auliard, CB Levaché, P Cailleux, F Schaeffer, N Albin, D Sévin-Robiche, J Domas, S Ellis, P Montcuquet, GA Baumont, M Bégue, S Gréget, JL Ratoanina, A Vanoli, C Bielsa, M Bonichon-Lamichhane, D Jaubert, H Laharie-Mineur, L Alcaraz, E Legouffe, H Bourgeois, G Cartron, F Denis, O Dupuis, G Ganem, S Roche-Forestier, L Delzenne, E Chirat, JL Baticle, E Béguier, S Jacquot, E Janssen, H Lauché, A LeRol, JP Chantelard, GA L'Helgoualc'h, EC Antoine, A Kanoui, JF Llory, JM Vannetzel, J Vignoud, C Bruna, T Facchini, K Moutel-Corviole, A Voloch, A Ghoul, D Loiseau, N Barbet, N Dohollou, K Yakendji
Publikováno v:
Lancet (London, England). 393(10191)
Summary Background In 2013, the interim analysis of the Protocol for Herceptin as Adjuvant therapy with Reduced Exposure (PHARE) trial could not show that 6 months of adjuvant trastuzumab was non-inferior to 12 months. Here, we report the planned fin
Autor:
L. Roca, PH Cottu, H. Orfeuvre, Bernard Asselain, Frank Mayer, Christine Levy, J-L Canon, Thomas Bachelot, M. Spielmann, J-P. Machiels, Lionel Uwer, Jérôme Lemonnier, H. Roche, D. Verhoeven, T Facchini, J-C Eymard, T Wiston, D Jaubert, Magali Lacroix-Triki, P. Kerbrat, H. Wildiers, M. Campone
Publikováno v:
Cancer Research. 76:P1-12
Background: Ixabepilone, an epothilone B analog, has demonstrated single-agent activity in metastatic and neoadjuvant settings. The PACS08 trial aimed to compare adjuvant FEC100-Docetaxel regimen to FEC100-Ixabepilone in poor prognosis early breast c
Autor:
Anne Motte, Noémie Jourde-Chiche, René Gerolami, Valérie Moal, D. Jaubert, Tristan Legris, Lucie Fages, Henri Vacher-Coponat, Patrick Borentain, Philippe Colson
Publikováno v:
Journal of Clinical Microbiology. 53:1523-1530
Hepatitis E virus (HEV) genotype 3 is endemic in Europe and hyperendemic in southern France. Recent reports of a high prevalence of HEV RNA in blood donations and in culinary specialties from this geographical area confirmed the endemicity of HEV and
Autor:
J-C Eymard, H. Roche, Anne-Laure Martin, PH Cottu, M. Spielmann, M. Campone, D Jaubert, Triki M Lacroix, J-P. Machiels, Thomas Bachelot, J-L Canon, Lionel Uwer, H. Wildiers, Christine Levy, H. Orfeuvre, Bernard Asselain, P. Kerbrat, L. Roca, F. Mayer, D. Verhoeven, T Facchini, T Winston
Publikováno v:
Cancer Research. 71:P5-18
Purpose: PACS 01 trial demonstrated that the sequential adjuvant chemotherapy with FEC100 followed by docetaxel (D) significantly improves disease-free and overall survival in node-positive(N+) early breast cancer (BC). However, Triple negative (TN)
Publikováno v:
Progrès en Urologie. 21:793-797
Resume La place de la dietetique est fondamentale dans le traitement de l’insuffisance renale chronique (IRC). Les prescriptions dietetiques doivent tenir compte du stade de l’IRC. Avant le stade de la dialyse, les objectifs sont d’eviter d’a
Autor:
E. Levy, Xavier Pivot, V. Grangé, Elsa Curtit, D. Jaubert, L. Cals, P. Nouyrigat, N. Maille, T. Facchini, Joseph Gligorov, Alain Lortholary, N. Dohollou
Publikováno v:
European Journal of Cancer. 47:2396-2402
Aim Non-pegylated liposomal doxorubicin (NPLD) has demonstrated equivalent antitumour activity to conventional doxorubicin and a significantly lower risk of cardiotoxicity when given as a single agent or in combination with cyclophosphamide. This pha
Autor:
N Jovenin, D Jaubert, Michel Marty, C Benoit, Dominique Spaeth, P. Piedbois, L Puyuelo, Daniel Serin, A Radji, M Resbeut, D Cowen, S Clippe, H El Amiri, Marc Buyse, J-M Ferrero
Publikováno v:
Cancer Research. 70:P5-11
Rationale: Issues have been reported with aromatase inhibitors (AI) compliance in adjuvant breast cancer. The present study was performed in order to better assess patient (pt) compliance, and to test whether educational material (EM) can improve com